Scisparc and clearmind continue to strengthen international patent portfolio with next generation classic psychedelic-based compounds

Tel aviv, israel, feb. 20, 2024 (globe newswire) -- scisparc ltd. (nasdaq: sprc) ("company" or "scisparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part of its ongoing collaboration with clearmind medicine inc. (“clearmind”) (nasdaq: cmnd) (cse: cmnd) (fse: cwy), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, clearmind filed three patent applications under the international patent cooperation treaty.
SPRC Ratings Summary
SPRC Quant Ranking